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Abstract
Background: Lung cancer is the most common malignancy in humans and its high fatality means that no effective
treatment is available. Developing new therapeutic strategies for lung cancer is urgently needed. Malaria has been reported
to stimulate host immune responses, which are believed to be efficacious for combating some clinical cancers. This study is
aimed to provide evidence that malaria parasite infection is therapeutic for lung cancer.
Methodology/Principal Findings: Antitumor effect of malaria infection was examined in both subcutaneously and
intravenously implanted murine Lewis lung cancer (LLC) model. The results showed that malaria infection inhibited LLC
growth and metastasis and prolonged the survival of tumor-bearing mice. Histological analysis of tumors from mice
infected with malaria revealed that angiogenesis was inhibited, which correlated with increased terminal deoxynucleotidyl
transferase-mediated (TUNEL) staining and decreased Ki-67 expression in tumors. Through natural killer (NK) cell cytotoxicity
activity, cytokine assays, enzyme-linked immunospot assay, lymphocyte proliferation, and flow cytometry, we demonstrated
that malaria infection provided anti-tumor effects by inducing both a potent anti-tumor innate immune response, including
the secretion of IFN-c and TNF-a and the activation of NK cells as well as adaptive anti-tumor immunity with increasing
tumor-specific T-cell proliferation and cytolytic activity of CD8
+ T cells. Notably, tumor-bearing mice infected with the
parasite developed long-lasting and effective tumor-specific immunity. Consequently, we found that malaria parasite
infection could enhance the immune response of lung cancer DNA vaccine pcDNA3.1-hMUC1 and the combination
produced a synergistic antitumor effect.
Conclusions/Significance: Malaria infection significantly suppresses LLC growth via induction of innate and adaptive
antitumor responses in a mouse model. These data suggest that the malaria parasite may provide a novel strategy or
therapeutic vaccine vector for anti-lung cancer immune-based therapy.
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Introduction
Lung cancer is the leading cause of cancer-related deaths
worldwide [1]. Although treatment methods in surgery, irradia-
tion, and chemotherapy have been improved, prognosis remains
unsatisfactory, and developing new therapeutic strategies is still an
urgent demand. Immunotherapy may represent one of new
therapeutic strategies for lung cancer has recently been developed
[2–5]. The goal of lung cancer immunotherapy is to augment the
weakened host immune response against tumors using specific
and/or nonspecific immune stimulants [4–6]. Nonspecific im-
munostimulatory agents and interventions with cytokines have
limited clinical benefits. The target-directed immunotherapy with
defined tumor antigens, such as melanoma-associated antigen 3
and mucin 1(MUC1), are suboptimal and strong adjuvant agents
are needed [6,7]. In addition, it is now clear that lung cancer often
present a tolerogenic microenvironment that hampers effective
antitumor immunity. Therefore, new potent and efficacious
immunotherapy, both augmenting antitumor immunity and
counteracting tumor-mediated immunosuppression for lung can-
cer are needed.
Malaria, which is caused by an intracellular parasite from the
Plasmodium genus, is the most common parasitic infection in
humans. Human malaria parasite infection can produce periodic
high fevers in the acute phase. Hyperthermia has been clinically
used for the treatment of certain cancers [8–11]. Furthermore,
malaria has been reported to stimulate host immune responses,
such as promoting IFN-c production, activating natural killer (NK)
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dendritic cells (DCs), and stimulating T-cell proliferation [12,13],
which are believed to be efficacious for combating some clinical
cancers [14–16].
In this study, we propose that malaria parasite infection is
therapeutic for lung cancer. The antitumor effect and immuno-
logical mechanisms of malaria infection was studied in a murine
lung cancer model. We found that Plasmodium yoelii 17XNL
(P. yoelii 17XNL) infection significantly inhibited the growth and
metastasis of Lewis lung cancer (LLC). Furthermore, we
demonstrated that malaria infection provided antitumor effect
by inducing potent innate and adaptive antitumor immunity.
Results
Suppression of LLC growth and metastasis development
in mice by malaria parasite infection
To determine the effect of malaria infection on the growth
of LLC cells, we infected tumor-bearing mice seeded with
a subcutaneous (s.c.) injection of LLC cells with P. yoelii 17XNL
parasitized erythrocytes (LLC+Py) or with an equivalent number
of uninfected erythrocytes (LLC). During the infectious period of
malaria (Fig. S1), the growth of tumor cells was clearly suppressed
in the LLC+Py group compared to the LLC group (Fig. 1A&B).
The tumor volumes (P=0.0006, Fig. 1A) and tumor weights
(P,0.0001, Fig. 1B) were significantly decreased in the LLC+Py
group mice as compared with the LLC group mice. We then
determined the effect of malaria parasite infection on lung cancer
metastasis by analyzing the occurrence of distant metastases in the
lung and liver on day 35 post-tumor cell inoculation. We found
that whereas the LLC control group exhibited a high frequency of
metastasis (10 of 10 mice, 100%), metastasis in the LLC+Py group
was only observed in 1 of 10 animals (P,0.0001, Fig. 1C and Fig.
S2). This experiment was then performed using a more aggressive
metastatic model produced by intravenously (i.v.) injection of
tumor cells into the mice [17]. Similar to the previous s.c. tumor
model, malaria parasite infection significantly reduced the number
of metastases that developed in the lung (P=0.0057, Fig. 1D&E).
In addition, malaria parasite-infected tumor-bearing mice survived
much longer than their uninfected counterparts (P=0.0002,
Fig. 1F). Distant metastases are a major reason for cancer-related
death in patients with solid tumors [18]. Therefore, we combined
surgical treatment and malaria infection to verify its antimetastatic
activities. The primary tumor was surgically removed after tumor
formation. Five days later, half of the mice were infected with P.
yoelii and the others were uninfected (Fig. 2A). The results showed
that parasite-infected tumor-bearing mice survived much longer
than their uninfected counterparts after surgery (P=0.0246,
Fig. 2B). This observation hints toward effects of malaria parasite
infection against late steps in the metastatic process after invasion
of the blood vessels by metastatic tumor cells.
Effect of malaria parasite infection on tumor cell
proliferation, apoptosis, and angiogenesis
As shown in Figure 3, staining for the proliferation marker Ki67
shows significant suppression of proliferation in the LLC+Py group
mice, compared with the LLC group mice (P=0.0022, Fig. 3A).
Meanwhile, apoptosis cells were markedly increased within tumors
of the LLC+Py group mice versus the LLC group mice
(P=0.0079, Fig. 3B), as evidenced by terminal deoxynucleotidyl
Figure 1. Malaria parasite infection suppresses tumor growth and metastasis in a mouse model. A, Tumor growth was measured over
time (n=12). The graph shows average with SD. B, Tumor mass 17 days after tumor cell inoculation (n=10). C, Metastasis development 35 days after
tumor inoculation. The graph shows the number of lung and liver tumors in the LLC and LLC+Py mice (n=10). D, Number of lung tumor nodules in
mice 18 days after intravenous tumor inoculation (n=21). E, Examples of metastatic nodules in the lungs of mice in D. F, Survival curve of LLC and
LLC+Py group mice (n=11). All experiments were performed three times with similar results. Statistical differences between groups are indicated by
the P values.
doi:10.1371/journal.pone.0024407.g001
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Then, tumor blood vessels were examined to determine whether
the observed decrease in proliferation and increase in apoptosis
were affected by vascular pruning [19]. Staining of endothelial
cells in blood vessels with CD31 showed extensive tumor
vasculature between tumor nests in the LLC group mice versus
marked angiogenic suppression in the LLC+Py group mice
(P=0.0022, Fig. 3C and Fig. S3).
Induction of Th1-type cytokines and increasing of NK-cell
cytotoxicity activity and infiltration
The potent anti-tumor activity of malaria infection greatly
encouraged us to further explore its profound mechanism. The
innate immune system which is believed to produce protective
cytokines and activate innate lymphocytes provides the way to
quickly resist tumor [20]. We found that malaria parasite infection
led to rapid increases in IFN-c and TNF-a levels, peaking 3 days
after infection (Fig. 4A&B), and the lytic activity of NK cells was
significantly increased during the early stages of infection (Fig. 4C).
Although the percentage of NK cells in tumor-draining lymph
nodes (TdLNs) was not significantly different between the groups
(Fig. 4D), parasitic infection increased the number of granzyme
B-secreting NK cells in TdLNs (Fig. 4E). An increase in both the
number of NK cells and granzyme B-secreting NK cells was
observed in tumor tissue in the LLC+Py group (Fig. 4F&G),
suggesting that after parasitic infection, tumor-infiltrating NK cells
exhibit higher in situ cytotoxic activity. These results confirmed
that malaria infection had a function in the activation of the innate
immune response that acts to control the growth of inoculated
LLC cells.
Induction of anti-tumor-specific immune responses
Because of the weak immunogenicity of LLC cells, studying the
antigen (Ag)-specific immune response to LLC cells is challenging
[21]. Therefore, we generated a recombinant LLC cell line
(LLC-MUC1) that expressed MUC1 (Fig. S4) to examine the
tumor Ag-specific immune responses induced by malaria parasite
infection. In order to further confirm the immune responses to be
tumor Ag-specific, not mouse-self Ag-specific, we used an
exogenous MUC1 (human MUC1) to generate the LLC-MUC1
cell line. Human MUC1 is highly immunogenic in mice and its
epitope is very clear so that it is convenient for us to examine the
tumor Ag-specific immune responses. LLC-MUC1 cells and the
parental LLC cells did not show any significant difference in
growth and morphological characteristics in vitro, and also
displayed a similar growth rate in vivo (data not shown).
Given the central role of DCs in initiating and maintaining Ag-
specific immune responses [20,22–24], we analyzed the percent-
age and the maturation of CD11C
+ DCs in the lymph node (LN)
in tumor-bearing mice infected with P. yoelii 17XNL parasitized
Figure 2. The antimetastatic effect of malaria infection after tumor surgery in mice. A,5 610
5 LLC cells were injected s.c. into the right
flank of C57BL/6 mice. After 15 days of tumor growth, primary tumors were surgically removed. Mice were followed for an additional 5 days to
recovery, then half of the mice were infected with P. yoelii 17XNL and the others were injected with an equivalent number of uninfected erythrocytes.
B, Data shows the survival curves of mice after primary tumor removal. P. yoelii 17XNL infected mice survived much longer than their uninfected
counterparts (n=11).
doi:10.1371/journal.pone.0024407.g002
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staining (left) and assay quantification (right, n=5–6) for Ki-67 (A), TUNEL (B), and CD31 (C) analyses of the tumor samples in Fig. 1B. Each symbol
corresponds to an individual animal. The line represents the mean value. Bars: 25 mmi nA ,5 0mm in B and C.
doi:10.1371/journal.pone.0024407.g003
Figure 4. Malaria parasite infection induces the production of Th1-type cytokines and increases NK cell cytotoxicity activity. A and
B, Levels of IFN-c (A) and TNF-a (B) in splenocyte culture supernatants as measured by ELISA (n=4). C, The cytotoxicity of NK cells enriched from
splenocytes at various time points was assessed against YAC-1 cells at the indicated effector-to-target (E:T) ratios (n=4). D and E, Five days after
tumor inoculation, the percentage (D) and the granzyme B-secretion (E) of NK cells were determined in TdLN and TnLN of mice by flow cytometry
(n=6). F and G, The absolute numbers of tumor-infiltrating NK cells (F) and spontaneous granzyme B-producing NK cells (G) were quantified by flow
cytometry and normalized to biopsy weight (n=6) 17 days after tumor inoculation. These experiments were independently performed three times
with identical results, and the representative scatter plots are shown. All graphs show average with SD. *, P,0.05.
doi:10.1371/journal.pone.0024407.g004
Immunotherapy for Lung Cancer by Malaria Infection
PLoS ONE | www.plosone.org 4 September 2011 | Volume 6 | Issue 9 | e24407erythrocytes (LLC+Py) or uninfected erythrocytes (LLC). We
found that malaria infection at early stage increased the percent of
CD11C
+ DCs (Fig. 5A and Fig. S5) and up-regulated CD80 and
CD86 expression by CD11C
+ DCs in the tumor draining lymph
node (TdLN), as compared to the LLC group mice (Fig. 5B&C).
This increase in the percentage and maturation of DCs was not
observed in non-tumor draining lymph node (TnLN) of both
groups of mice (Fig. 5 and Fig. S5).
We then assessed whether malaria infected-associated DCs
enhancement translated into the improved cross-priming and
intra-tumor recruitment of specific T cells or not [25,26]. Using
our tumor mouse model with LLC-MUC1 cells, we assessed the
tumor-specific (MUC1 versus irrelevant OVA) production of
IFN-c and granzyme B in TdLN cells by enzyme-linked
immunospot (ELISPOT) assay. We observed a significant increase
in the numbers of IFN-c/granzyme B-secreting effector cells in
response to MUC1 (Ag-specific), but not to OVA, in the LLC+Py
group (Fig. 6A&B). This suggests that TdLN DCs in LLC+Py
group mice are competent to cross-prime peripheral tumor specific
T cells, eliciting MUC1-specific immune responses with higher
potency. To verify that the DC activated TdLN cells actually
migrated into tumor tissue, the density of tumor-infiltrating
leucocytes was examined. We found that in LLC+Py mice, there
was a dramatic increase in the density of tumor-infiltrating CD45
+
cells, and when tumor-infiltrating lymphocyte subsets were
examined, both CD4
+ and CD8
+ T cells populations were
increased with CD8
+ T cells representing the dominant cell type
(Fig. 6C). Among the CD8
+ T cells, the density of granzyme
B-expressing cells was also increased significantly in the tumors
from the LLC+Py group (Fig. 6C). These data suggested that
malaria infection promoted the accumulation of both CD4
+
T cells and CD8
+ T cells, and the CD8
+ T cells had increased the
effector function within the tumor.
We next examined the systemic anti-tumor immune response
and observed that the number of MUC1-specific IFN-c-producing
cells in the spleen was much higher in the LLC+Py mice compared
to the LLC mice (Fig. 6D). Among the granzyme B-producing cells
in the spleen, the number of MUC1-specific CD8
+ T cells was
significantly higher in the LLC+Py group relative to the LLC
group (Fig. 6E). We further measured tumor-specific T cell
proliferation and found that the Ag-specific proliferative ability of
splenocytes from the LLC+Py group mice was significantly higher
than that of the LLC group mice (Fig. 6F). These data suggested
that malaria infection induced the systemic anti-tumor immune
response.
Stimulation of effective, long-lasting anti-tumor
immunity
Malaria parasite infection resulted in prolonged survival and
complete tumor regression in 5–10% (1–2 per 20 mice) of the
infected tumor-bearing mice. The surviving animals rejected
subsequent subcutaneous injections of parent tumor cells on day
50 after the initial tumor inoculation, suggesting that they had
acquired systemic immunity against LLC cells. To assess whether
malaria parasite infection led to the generation of long-term
immunity, 50 days after tumor inoculation, splenocytes from the
mice exhibiting tumor regression were analyzed for Ag-specific
proliferation and IFN-c secretion. Splenocytes from the mice
exhibiting tumor regression proliferated considerably in response
to MUC1 peptides (Fig. 7A) and produced high levels of
Ag-specific IFN-c (Fig. 7B), indicating that malaria parasite
infection augmented not only in situ immunity but also long-
lasting, systemic tumor-specific immunity, contributing to the
inhibition of tumorigenesis and the rejection of tumor infiltration
at distant sites.
Antitumor effect of the combination of malaria parasite
infection and DNA vaccine treatment
Successful adjuvants help protective antigens to stimulate potent
and long-lasting immune responses. In the case of malaria, there
are several candidate molecules in malaria parasites that could act
as adjuvant components [27,28]. To evaluate whether the parasite
infection could enhance the immune response of lung cancer DNA
vaccine pcDNA3.1-hMUC1 [29], tumor-bearing mice were
immunized with monotherapy (LLC+DNA) or combination
therapy (LLC+Py+DNA), and animals infected with parasitized
erythrocytes (LLC+Py) or uninfected erythrocytes (LLC) served as
control groups. The results demonstrated that the combination of
malaria parasite infection and DNA vaccine treatment exerted
synergistic effects on the inhibition of tumor growth (Fig. 8A) and
the prolongation of mouse survival (Fig. 8B). These data suggest
that malaria parasite is a novel adjuvant that can facilitate specific
antitumor immunity.
Figure 5. Malaria infection increases the percentage and maturation of DC in TdLN. Two days after tumor inoculation, DC maturation
profile and numbers were determined in lymph node cells. A. Quantification of DC percentage in lymph nodes by flow cytometry. DC percentage in
TdLNs and TnLN of tumor bearing mice are shown. The line in graph indicates the mean value. B and C, The geometric mean fluorescence intensity
of CD80 (B) and CD86 (C) on DCs, data are pooled from three independent experiments. The graph shows average with SD. *P,0.05; ** P,0.01;
*** P,0.001.
doi:10.1371/journal.pone.0024407.g005
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Tumors frequently interfere with the development and function
of immune response [30]. The ability of various infections to
suppress cancer growth has been well documented [31–34]. In the
present study, we examined antitumor and antimetastatic activities
of malaria infection in both subcutaneously and intravenously
implanted murine LLC model. Malaria parasite infection
inhibited LLC growth and metastasis and prolonged the survival
of tumor-bearing mice. Further histological analysis of tumors
from mice infected with malaria revealed that angiogenesis was
inhibited and the proportion of proliferative cells was decreased,
whereas apoptotic cells were increased. Malaria infection in
LLC-bearing mice also significantly increased the secretion of
IFN-c and TNF-a, the activation of NK cells, tumor-specific
T-cell proliferation, and cytolytic activity of CD8
+ T cells. These
results indicate that malaria parasite infection induces innate and
adaptive antitumor responses in LLC-bearing mice, leading to the
induction of antitumor and antimetastatic activities.
Lung cancer is the major cause of cancer-associated deaths. Its
high fatality means that no effective treatment is available [1].
Immunotherapy may represent one of new therapeutic strategies
for lung cancer has recently been developed. The goal of lung
cancer immunotherapy is to augment the weakened host immune
response against tumors using specific and/or nonspecific immune
stimulants. Traditional biological immunoadjuvants, such as
Bacillus Calmette-Gue ´rin (BCG) and diphtheria toxin, and
nonspecific immunostimulatory interventions with cytokines, such
as IL-2, IFN-a, and TNF-a, induce a massive influx of
inflammatory cells and the production of a Th1 cytokine profile
Figure 6. Malaria parasite infection induces anti-tumor-specific immune responses. A and B, IFN-c- (A) and granzyme B- (B) producing




+ T cells, and spontaneous granzyme B-producing CD8
+ T cells were quantified by flow cytometry and normalized to biopsy
weight (n=6) 17 days after tumor inoculation. D to F, Splenocytes were harvested 30 days after tumor inoculation. D, IFN-c production was
measured using an ELISPOT assay (n=6). E, CD8
+ T cells were enriched from splenocytes and subjected to ELISPOT assay to measure granzyme B
production (n=6). F, Proliferation of splenocytes was measured by BrdU incorporation (n=6). Data are presented as the stimulation index (SI), which
was calculated by determining the ratio of specific MUC1 peptides to non-specific OVA peptides. All graphs show average with SD. These
experiments were independently performed three times with identical results, and the representative scatter plots are shown. *, P,0.05; **, P,0.01;
***, P,0.001.
doi:10.1371/journal.pone.0024407.g006
Figure 7. Malaria parasite infection stimulates effective long-lasting anti-tumor immunity. A and B, P. yoelii 17XNL infection resulted in
complete tumor regression in 5–10% (1–2 per 20 mice) of the infected tumor-bearing mice. Fifty days after infection, splenocytes from the mice
exhibiting tumor regression were analyzed for MUC1-specific proliferation (A) and IFN-c secretion (B) (n=4). The line in A indicates the mean value.
Bars in B represent SD. ***P,0.001.
doi:10.1371/journal.pone.0024407.g007
Immunotherapy for Lung Cancer by Malaria Infection
PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e24407that leads to affirmative efficacy in the treatment of some cancers
[5]. However, the induction of the desired immune responses is
weak, responses are short lived, and memory formation is
defective. Thus, non-specific immune simulation has not shown
a clear benefit for lung cancer in either preclinical or clinical
efforts. Like most pathogens [31–34], malaria parasite induces a
massive influx of inflammatory cells and production of a Th1
cytokine profile that leads to an immune response against tumor
cells. Notably, malaria parasite infection induces not only non-
specific antitumor immunity but also tumor-specific immunity. In
addition, malaria infection generates effective and long-lasting
local and systemic antitumor immunity.
Current antitumor specific immunotherapy such as therapeutic
vaccines is still suboptimal. The immunoadjuvant component is
needed to create a proinflammatory milieu, thereby enhancing
costimulation and T lymphocyte activation [35]. In addition, the
tumor microenvironment is potently immunosuppressive as a
result of rapid functional inactivation of specific immunotherapy-
induced effector lymphocytes that manage to home to the tumor
microenvironment [6]. However, malaria parasite infection
increases the percentage of DCs, up-regulates CD80 and CD86
expression of DCs in TdLN, promotes the maturation of DCs, and
delivers costimulation signals that result in the generation of T cells
with an activated phenotype. Activated CD4
+ T cells produce an
array of cytokines leading to the generation and clonal expansion
of tumor-specific CD8
+ T cells with cytolytic activity which
recognize and kill tumor cells [20]. Furthermore, malaria parasite
infection augments CD8
+ T-cell-mediated antitumor immunity
through increased number and effector function both in the
TdLNs as well as in the tumor itself. Malaria parasite infection also
promotes tumor-infiltrating NK cells that exhibit high cytotoxic
activity in the tumor microenvironment.
Malaria parasite infections profoundly provoke the host
immune system, inducing polyclonal activation, massive prolifer-
ation and differentiation of lymphocytes with parasite-unrelated
specificities as well as immune responses to host antigens released
during malaria parasite infection [36–41], which may serve as
enhanced immune surveillance mechanisms against lung cancer.
Possibly, the pre-existing antibodies and pre-activated non-tumor-
specific responses together with the tumor-Ag-specific humoral
and cellular responses initiated after the parasite infection might
inhibit early stage tumorigenesis. Then, when malaria parasite
infection is acquired during lung cancer growth and development,
the innate and adaptive immune responses may be further induced
and/or enhanced and strongly suppress tumor growth and
metastasis. In addition, there are several candidate molecules in
malaria parasites that could act as adjuvant components [27,28].
The glycosylphosphatidylinositol (GPI) of P. falciparum is believed
to be an important factor in the induction of proinflammatory
responses mainly through Toll-like receptor(TLR)2/MyD88-
mediated signaling [42]. Hemozoin, a bio-crystalline substance,
is a hemin detoxification by-product of malaria parasites, have
been shown to mediate innate immune system activation through
TLR9 [27,28]. Hemozoin also shows a potent adjuvant effect with
several model antigens. The ‘‘built-in’’ adjuvant may facilitate the
specific antitumor effect in our study. Taken together, the malaria
parasite may be an ideal vaccine vehicle not only for presentation
of lung cancer antigens (such as MUC1) to tumor-specific T-cells,
but also act as an adjuvant to provide the appropriate milieu to
enhance the efficacy of these effector cells [43–45].
However, our studies have two clear limitations. First, there is
no fever in rodent malaria [46,47], which was also observed in our
study (data not shown). Therefore, there should be no hyperther-
mia effect in our rodent malaria-cancer models. Second, the anti-
cancer effects have been confirmed to be much stronger in mice
with relatively longer natural disease course (approximately four
weeks) of P. yoelii infection compared to those with a shorter
disease course (approximately two weeks) of P. chabaudi infection or
those with interrupted short courses of P. yoelii infection (two
weeks, following antimalarial drug treatment, data not shown).
That means the longer infectious period it is, the stronger effect on
the inhibition of lung cancer growth it will be. Unfortunately, the
longest period of rodent malaria infection is only maintained four
weeks (P. yoelii). So we couldn’t observe the effect of long-term
malaria infection on the cancer growth. However, one of the
benign forms of human malaria parasite P. vivax produces periodic
high fevers in the acute phase, and this parasite subsequently
survives for years during the chronic phase of infection if the
patient forgoes treatment [48,49]. Hence, we hypothesize that a
long course of therapeutic malaria for human lung cancer should
be effective.
Despite Greentree proposed the macrophage activation-based
hypothesis of therapeutic malaria (malariotherapy or malar-
iatherapy) for cancer in 1981[50], the positive relationship
between malaria and some virus-associated cancers (such as
Burkitt’s lymphoma and cervical cancer) has been well
documented [51,52]. However, we report here that malaria
infection significantly suppresses LLC growth via induction of
innate and adaptive antitumor responses, which provides a novel
Figure 8. Combination of malaria parasite infection and DNA
vaccine treatment produces a synergy antitumor effect. A and
B,5 610
5 LLC-MUC1 cells were injected s.c. into the flank region of mice.
Four groups (LLC, LLC+DNA, LLC+Py, and LLC+Py+DNA) of mice were
immunized with DNA vaccine or infected with parasites as described in
Materials and Methods and subsequently monitored for tumor
development for 40 days (A) and determined the survival end point
for 80 days (B). The graph of (A) shows average with SD. Statistical
differences between groups are indicated by the P values.
doi:10.1371/journal.pone.0024407.g008
Immunotherapy for Lung Cancer by Malaria Infection
PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e24407understanding of the relationship between malaria and lung cancer.
Wesuggestthattheurgentneedistoexplorethefeasibilityofusinga
gene-modified attenuated Plasmodium as a lung cancer vaccine
vector and to identify the active cellular components of malaria
parasite for immunotherapy for lung cancer.
Materials and Methods
Ethics Statement
The animal experiment facilities were approved by the
Guangdong Provincial Department of Science and Technology,
the approval ID is SYXK (Guangdong) 2005-0063, and complied
with the guidelines of the Animal Care Committee, Guangzhou
Institutes of Biomedicine and Health, Chinese Academy of
Sciences (Animal Welfare Assurance #A5748-01). All surgery
was performed under anesthesia, and all efforts were made to
minimize animal suffering.
Mice, cells, and parasites
Female 8- to 10-week-old C57BL/6 mice were purchased from
the Vital River Experiment Animal Limited Company (Beijing,
China) and raised in the Animal Center of the Guangzhou
Institutes of Biomedicine and Health in accordance with the
Guide for the Care and Use of Laboratory Animals established by
this institute. The murine LLC cell line and YAC-1 lymphoma
cells were obtained from the Chinese Academy of Sciences Cell
Bank (Shanghai, China). The pcDNA3.1 plasmid expressing
human mucin 1(MUC1) [29], obtained from Dr. June-Key Chung
(Seoul National University College of Medicine, Seoul, Korea),
was stably transfected into LLC cells with Lipofectamine
(Invitrogen, Carlsbad, CA) [53] and selected with neomycin
(G418; Sigma, Saint Louis, MO, USA) to generate an
LLC-MUC1 cell line. MUC1 expression levels were confirmed
by western blotting [53,54]. The nonlethal P. yoelii 17XNL strain
was obtained from the Malaria Research and Reference Reagent
Resource Center (MR4).
Tumor Growth and Metastasis Inhibition Assay
To establish tumors, C57BL/6 mice were s.c. injected with
5610
5 murine LLC cells. At the same time, the tumor cell-
inoculated mice were infected with 5610
5 P. yoelii 17XNL-
parasitized erythrocytes (LLC+Py). Mice injected with LLC cells
and challenged with non-infected erythrocytes were used as the
control group (LLC). Animals were examined daily until the
tumors became palpable, after which the tumor volume was
determined daily by measuring the diameter of the tumors using
calipers. The volume was calculated using the formula, V=(ab
2)/2,
where a is the long axis, and b is the short axis. To assess tumor
metastasis following primary tumorigenesis, 5610
5 LLC cells were
injected s.c. into the right flank. After 35 days of tumor growth, the
mice were sacrificed, and metastasis to the lung and liver was
determined by counting individual metastatic nodules. Paraffin
slides of tissue were analyzed for tumor cell apoptosis and
proliferation, as well as tumor angiogenesis and metastasis as
described previously [19]. To analyze the effect of malaria parasite
infection on metastasis in the intravenous tumor cell model, the
mice were injected with 5610
5 LLC cells i.v. via the tail vein and
followed for 18 days before metastasis was analyzed. Metastasis
development was evaluated by counting individual metastatic
nodules. To evaluate the antimetastatic effect of malaria infection
after surgery, 5610
5 LLC cells were injected s.c. into the right
flank of C57BL/6 mice. After 15 days of tumor growth, primary
tumors were surgically removed. Mice were followed for an
additional 5 days to recover, and then half of the mice were
infected with P. yoelii 17XNL and the others were injected with
equivalent number of uninfected erythrocytes. The survival end
point was determined by either spontaneous death of the animal or
because of the presence of moribund signs. In all experiments,
treatment groups were randomized to prevent cage effects.
Lymphocyte isolation
The generation of single-cell suspensions from the spleen and
lymph nodes was described previously [55,56]. Isolation of NK
and CD8
+ T cells from splenocytes was performed using anti-
mouse DX5 and CD8a MicroBeads, respectively, according to the
manufacturer’s instructions (Miltenyi Biotec, Bergisch Gladbach,
Germany). The purity of the selected cell populations was
determined by flow cytometry. For analysis of tumor-infiltrating
lymphocytes, tumor-bearing mice were sacrificed 17 days after
malaria parasite infection, and the subcutaneous tumors were
harvested. To prepare single-cell suspensions, tumors were
digested in a mixture of 0.1% collagenase type IV (Worthington,
Lakewood, NJ, USA) and 0.01% DNase I (Roche, Indianapolis,
IN, USA) in RPMI-1640. The tumors were then disrupted using
a cell strainer, and viable lymphocytes were collected after
carrying out cell separation in a Ficoll gradient [57].
Flow cytometry
The following antibodies and their corresponding isotype
controls (all purchased from eBioscience, San Diego, CA, USA)
were used for staining: CD45-PE, NK1.1-APC, CD4-FITC,
CD11c-FITC, CD80-PE, CD86-PE, CD3-Percp-cy5.5, CD3-PE,
CD8-APC, and CD8-PE. After adding the appropriate antibody,
the cells were incubated in the dark at 4uC for 30 minutes and
then washed twice with FACS buffer (0.1% BSA and 0.05%
sodium azide in PBS). For intracellular granzyme B staining, the
cells were first stained with either CD8- or NK1.1-APC followed
by fixation and permeabilization, and the cells were then stained
with granzyme B-PE (eBioscience). Flow cytometry samples were
acquired on a BD FACSAria and analyzed with FlowJo software
(Tree Star, Inc.)
Cytokine assays (ELISA)
Splenocytes were cultured at a concentration of 10
7 cells/ml in
RPMI-1640. After incubation for 48 h, culture supernatants were
harvested and assayed for cytokine levels by two-site sandwich
enzyme-linked immunosorbent assay (ELISA) [58].IFN-c and
TNF-a were assayed using pairs of capture and detection
antibodies (R&D Systems, Minneapolis, MN, USA) according to
the manufacturer’s instructions. Cytokine levels were calculated
using standard curves determined by recombinant murine
cytokines.
NK cell cytotoxicity
CytoTox 96nonradioactive cytotoxicity assay (Promega) was
used to measure the specific lytic activity of NK cells in treated
mice (4 mice per group) according to the manufacturer’s protocol.
Cell proliferation analysis
Splenocyte proliferation was assessed using a BrdU colori-
metric ELISA (Roche) as recommended by the manufacturer. In
brief, splenocytes were incubated with 10 mg/ml MUC1
(HGVTSAPDTRPAPGSTAPPA) peptides or the irrelevant
peptide OVA (SIINFEKL) as a control for 72 h. 16BrdU was
added to the wells for 18 h and BrdU incorporation into newly
synthesized DNA strands was detected exactly as recommended by
the manufacturer.
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All ELISPOT reagents were purchased from R&D Systems.
Lymph node and spleen cells were used as responders in an IFN-c
and granzyme B ELISPOT assay as previously described [59].
Cells were stimulated with the MUC1 peptide (10 mg/ml) or OVA
peptide (10 mg/ml, negative control). Briefly, PVDF membrane
plates (Millipore, Bedford, MA, USA) were coated with an anti-
murine capture antibody (R&D Systems) overnight at 4uC.
Effector cells were added to triplicate wells at specified
concentrations, then co-cultured with the MUC1 peptide
(10 mg/ml) or OVA peptide (10 mg/ml, negative control) for
18 h at 37uC. The plates were washed and the biotinylated anti-
murine detection antibody was added. Plates were incubated for
2 h, and a Streptavidin-conjugated alkaline phosphatase (1:100 in
PBS-T, R&D Systems) was added for 1 h. Spots were visualized
with BCIP/NBT phosphatase substrate (R&D Systems) and
subjected to automated evaluation using the ELISPOT Reader
(CTL Limited). The mean numbers of spot-forming cells were
calculated from the triplicate assays.
Therapeutic Combination
To evaluate the combination effect of malaria parasite infection
and DNA vaccine (expressing MUC-1) treatment, 5610
5 LLC-
MUC1 cells (recombinant cell line that expresses MUC1, Fig S4)
were injected s.c. into the flank region. The mice were then
divided randomly into 4 groups (n=11): LLC, LLC+DNA,
LLC+Py, and LLC+Py+DNA. The parasite infection groups were
injected i.p. with 5610
5 P. yoelii 17XNL-parasitized erythrocytes
on the same day. The control mice received an equivalent number
of uninfected erythrocytes. The DNA vaccine-treated groups were
immunized intramuscularly on day 4, 10 and 15 after tumor
inoculation. The development of tumors in individual mice was
monitored every 3 days. The survival end point was determined by
either spontaneous death of the animal or because of the presence
of moribund signs.
Statistical Analyses
For parametric data, differences between groups were analyzed
with unpaired two-tailed Student’s t-tests; for nonparametric data,
differences between groups were analyzed with the Mann-Whitney
test. Survival curves were analyzed by a log-rank test. All statistical
analyses were performed with GraphPad Prism software.
Supporting Information
Figure S1 Dynamics of parasitemia in mice. Parasitemia
(percentage of infected erythrocytes versus total red blood cell
count) in naı ¨ve C57BL/6 mice (Py) and LLC-bearing C57BL/6
mice (LLC+Py) infected with Plasmodium yoelii 17XNL. Blood
smears were performed every 3 days, stained with Giemsa, and
counted, n=12. The graph shows average with SD.
(TIF)
Figure S2 Malaria parasite infection prevents metasta-
sis formation in mice. H&E-stained paraffin slides of the lungs
and livers of tumor-bearing mice infected with P. yoelii 17XNL
(LLC+Py) or that were infected with an equivalent number of
uninfected erythrocytes (LLC). Arrows show metastasis of tumors
in the lungs and livers of mice.
(TIF)
Figure S3 Malaria parasite infection inhibits tumor
angiogenesis. H&E-stained paraffin slides of tumor tissues from
tumor-bearing mice infected with P. yoelii 17XNL (LLC+Py) or
that were infected with an equivalent number of uninfected
erythrocytes (LLC). Arrows show blood vessels within the tumor.
(TIF)
Figure S4 Expression of MUC1 in recombinant LLC
cells (LLC-MUC1). The lysates of LLC-MUC1 or LLC cells
were separated by SDS-PAGE, blotted, and probed with anti-
MUC1 antibody and anti-GAPDH antibody as controls.
(TIF)
Figure S5 Malaria infection increases the percentage of
DC in TdLN. Four days after tumor inoculation, quantification
of DC percentage in lymph nodes of mice by flow cytometry. DC
percentage in TdLN and TnLN of tumor bearing mice are shown.
The graph shows average with SD. *** P,0.001.
(TIF)
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